No news, no promotions, no financial statements, nothing to reverse the negative trend for Generex Biotechnology Corporation (OTC:GNBT) recently. Even financial forum activity for this company is not what it used to be not so long ago. Hopes for better stock performance are mainly associated with optimistic results for the products of the company. 
Ever since the last trading frenzy for this stock in March, GNBT has been slowly declining. Currently, the stock price gravitates in the $0.2 levels as the daily trading volume rarely reaches 1 million. What is more interesting, while this company is not in its best financial condition, it is not that bad to negatively affect the stock price. Among other figures, the 10-Q with an end date Jan, 31st includes:
- $7.9 million in total current assets;
- $7.1 in total current liabilities;
- $5.2 million in net loss; [BANNER]
Now, not the best results out there, but not unusual for a biotechnology corporation in such stage of its development. There is cash at hand to support the operations and there are rarely promotions to distort the stock price, so it all comes to real measurable results to come.
Generex has two products in the pipeline – the Oral-lyn and the Glucose RapidSpray. According to the company website, the first one is towards the end of Phase3 Trial, which means there might be another trading frenzy coming. Ultimately, depending on what results Generex would announce, its stock would head back to the levels from previous years, or just continue on the way to sub-penny levels.
